Sanofi Research and Development Expenses 2010-2024 | SNY

Sanofi annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Sanofi research and development expenses for the quarter ending September 30, 2024 were $2.036B, a 12.51% increase year-over-year.
  • Sanofi research and development expenses for the twelve months ending September 30, 2024 were $7.754B, a 8.5% increase year-over-year.
  • Sanofi annual research and development expenses for 2023 were $7.282B, a 3.06% increase from 2022.
  • Sanofi annual research and development expenses for 2022 were $7.065B, a 4.92% increase from 2021.
  • Sanofi annual research and development expenses for 2021 were $6.734B, a 6.63% increase from 2020.
Sanofi Annual Research and Development Expenses
(Millions of US $)
2023 $7,282
2022 $7,065
2021 $6,734
2020 $6,316
2019 $6,740
2018 $6,961
2017 $6,185
2016 $5,723
2015 $5,643
2014 $6,413
2013 $6,336
2012 $6,330
2011 $6,701
2010 $5,844
2009 $6,391
Sanofi Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $2,036
2024-06-30 $1,835
2024-03-31 $1,866
2023-12-31 $2,017
2023-09-30 $1,810
2023-06-30 $1,777
2023-03-31 $1,678
2022-12-31 $1,882
2022-09-30 $1,748
2022-06-30 $1,764
2022-03-31 $1,671
2021-09-30 $1,702
2021-06-30
2021-03-31 $1,526
2020-09-30 $1,544
2020-03-31 $1,478
2019-09-30 $1,512
2019-03-31 $1,573
2018-03-31 $1,573
2017-12-31 $1,720
2017-09-30 $1,576
2017-06-30 $1,494
2017-03-31 $1,395
2016-12-31 $1,553
2016-09-30 $1,363
2016-06-30 $1,445
2016-03-31 $1,362
2015-09-30 $1,508
2015-06-30 $1,427
2014-06-30 $1,630
2013-06-30 $1,549
2012-06-30 $1,592
2012-03-31 $1,542
2011-12-31 $1,746
2011-09-30 $1,729
2011-06-30 $1,722
2011-03-31 $1,504
2010-12-31 $1,528
2010-09-30 $1,400
2010-06-30 $1,378
2010-03-31 $1,538
2009-12-31 $1,873
2009-09-30 $1,585
2009-06-30 $1,509
2009-03-31 $1,424
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $120.547B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $719.145B 74.49
Novo Nordisk (NVO) Denmark $464.190B 33.48
Johnson & Johnson (JNJ) United States $345.687B 14.02
AbbVie (ABBV) United States $303.100B 15.95
Merck (MRK) United States $251.749B 16.73
AstraZeneca (AZN) United Kingdom $199.805B 17.00
Novartis AG (NVS) Switzerland $197.798B 13.15
Pfizer (PFE) United States $146.038B 9.99
Innoviva (INVA) United States $1.122B 9.34